Valeant CEO Joseph Papa was on CNBC to discuss the company's first quarter 2018 earnings report, which for the first time since 2015 touted organic growth.
Here's what you should know.
1. Valeant's Salix Pharmaceuticals and its Bausch & Lomb segments accounted for 76 percent of Valeant's business. Combined, both products grew organically by 10 percent.
2. Mr. Papa also noted Salix's irritable bowel syndrome Xifaxan hit $1 billion in sales in the first quarter already.
3. He said drugs like Xifaxan will help Valeant pay down its $25 billion debt load.
4. Mr. Papa is betting on Valeant's research and development department to drive shareholder value and help the company improve its earnings.
5. He also referenced the company's decision to rename the company Bausch Health Companies.
https://www.beckersasc.com/supply-chain/valeant-no-more-valeant-pharmaceuticals-rebranding-as-bausch-health-companies.html